Evidence· July 12, 2026 · 17 min read
Topic
Infectious Disease
Vaccines, antivirals, HIV, PrEP, antimicrobial access, payer policy, and public-health commercialization.
Pricing & Access· July 11, 2026 · 16 min read
GSK Portfolio Dossier: ViiV HIV, Nucala Runway, and Oncology Rebuild
By Ran Chen#HIV#Respiratory#Infectious Disease
Evidence· July 6, 2026 · 16 min read
Azole Antifungal Adverse Events: FAERS By the Numbers
Approvals· June 30, 2026 · 18 min read
Utebzi (tebipenem pivoxil) FDA Approval: Stewardship & Launch Access
Pricing & Access· June 21, 2026 · 6 min read
Bicillin L-A Shortage: FDA's Lentocilin Importation and Billing Guidance
Evidence· June 17, 2026 · 14 min read
Fluoroquinolones in FAERS: 221,775 adverse-event reports by the numbers
Approvals· June 2, 2026 · 9 min read
Xocova (ensitrelvir) access guide: first oral COVID post-exposure prophylaxis
Approvals· June 2, 2026 · 9 min read
Zaynich (cefepime/zidebactam) access guide: novel AMR antibiotic for resistant cUTI
Pipeline· May 31, 2026 · 8 min read
Tebipenem HBr PDUFA preview for oral carbapenem access
By Ran Chen#PDUFA Date#FDA Approval#Infectious Disease
Pricing & Access· May 29, 2026 · 10 min read
Idvynso HIV access guide: PA criteria, switching, and affordability
By Ran Chen#HIV#Infectious Disease#Prior Authorization